Fidelity SPDR Advertisement
Home > Boards > Free Zone > Health and Sciences > Biotech Values

Recall Merck also tried to get an "improved

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
genisi Member Profile
 
Followed By 31
Posts 5,129
Boards Moderated 0
Alias Born 05/24/06
160x600 placeholder
France, Germany Seek More Power To Regulate Internet Firms
Europe escalated its war against U.S. technology superpowers as the Continent's two largest economies and the European Parliament on Thursday backed fresh efforts to rein in the growing influence of companies such as Apple Inc., Facebook Inc. and Google Inc.
More Top Equities Stories Of The Day
Telefónica Works to Redraw Its Empire
Spotify's Revenue Rose in 2013, But Losses Continued - 2nd Update
Canada Resident Caught Up in China Corruption Probe
Correction to La Compagnie Fares Story
SEC Grants Bank of America Short-Term Waiver from Hedge-Fund Restrictions
Deere Projects Sharp Decline in Farm-Equipment Sales -- 2nd Update
U.S. Stocks Close Higher
Kinder Morgan Unveils $6 Billion Debt Offer -- Update
genisi   Wednesday, 04/27/11 03:49:51 AM
Re: biomaven0 post# 118902
Post # of 184217 
Recall Merck also tried to get an "improved niacin" by targeting the same receptor with MK-0354, which despite significant decreases in FFAs levels and absence of flushing failed to demonstrate effects on HDL/LDL-Cholesterol and TGs in phase II. Obviously, being a GPR109A receptor agonist isn't all.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist